Large-scale manufacture of peptide therapeutics by chemical synthesis.
The large-scale commercial production of a 36-amino-acid peptide by chemical synthesis has been demonstrated in the development of enfuvirtide (T-20 or Fuzeon), a first-in-class membrane fusion inhibitor for the treatment of HIV. The rationale behind route selection and the scale-up of the process used to manufacture enfuvirtide are discussed.
Bray
Brian L
BL
Trimeris, Inc., 3518 West Gate Drive, Durham, Noth Carolina NC27707, USA. bbray@trimeris.com
D019380:Anti-HIV Agents / Q000138:chemical synthesis*; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41; D010446:Peptide Fragments / Q000138:chemical synthesis*
D019380:Anti-HIV Agents; D015700:HIV Envelope Protein gp41; D010446:Peptide Fragments; D000077560:Enfuvirtide